FDA — authorised 31 August 2010
- Application: NDA022184
- Marketing authorisation holder: ABBVIE
- Local brand name: LUMIGAN
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
🇺🇸 bimatoprost ophthalmic solution 0.03% in United States
FDA authorised bimatoprost ophthalmic solution 0.03% on 31 August 2010
Marketing authorisations
FDA
- Status: approved
bimatoprost ophthalmic solution 0.03% in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is bimatoprost ophthalmic solution 0.03% approved in United States?
Yes. FDA authorised it on 31 August 2010; FDA has authorised it.
Who is the marketing authorisation holder for bimatoprost ophthalmic solution 0.03% in United States?
ABBVIE holds the US marketing authorisation.